UBS Group reissued their sell rating on shares of AstraZeneca (LON:AZN) in a research report released on Thursday, Borsen Zeitung reports. They currently have a GBX 5,400 ($70.56) price objective on the biopharmaceutical company’s stock.

Other analysts have also issued research reports about the stock. Jefferies Financial Group reissued a buy rating and issued a C$15.00 price target on shares of Aphria in a research report on Friday, May 24th. Citigroup set a $13.00 target price on shares of e.l.f. Beauty and gave the company a hold rating in a report on Monday, May 13th. Goldman Sachs Group set a €76.30 ($88.72) target price on shares of Stroeer SE & Co KGaA and gave the company a buy rating in a report on Thursday. Shore Capital reissued a buy rating on shares of AstraZeneca in a report on Thursday. Finally, Liberum Capital reissued a sell rating on shares of Pendragon in a report on Thursday, June 27th. Three analysts have rated the stock with a sell rating, six have given a hold rating and ten have assigned a buy rating to the company’s stock. The stock currently has an average rating of Hold and a consensus target price of GBX 6,582.35 ($86.01).

LON AZN opened at GBX 7,005 ($91.53) on Thursday. The company has a 50 day simple moving average of GBX 6,385.84. AstraZeneca has a 12-month low of GBX 5,312 ($69.41) and a 12-month high of GBX 6,634 ($86.68). The company has a current ratio of 0.75, a quick ratio of 0.57 and a debt-to-equity ratio of 179.66. The company has a market capitalization of $90.58 billion and a price-to-earnings ratio of 36.87.

The company also recently announced a dividend, which will be paid on Monday, September 9th. Investors of record on Thursday, August 8th will be issued a dividend of GBX 71.90 ($0.94) per share. This represents a yield of 1.07%. The ex-dividend date is Thursday, August 8th. AstraZeneca’s dividend payout ratio (DPR) is presently 1.13%.

In other news, insider Marc Dunoyer bought 8,500 shares of the firm’s stock in a transaction that occurred on Tuesday, May 7th. The shares were acquired at an average price of GBX 5,800 ($75.79) per share, with a total value of £493,000 ($644,191.82). Also, insider Philip A. J. Broadley bought 520 shares of the firm’s stock in a transaction that occurred on Tuesday, April 30th. The shares were purchased at an average cost of GBX 5,738 ($74.98) per share, for a total transaction of £29,837.60 ($38,988.11).

About AstraZeneca

AstraZeneca PLC discovers, develops, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, autoimmunity, infection, neuroscience, and gastroenterology worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor, Plendil, Seloken/Toprol-XL, Tenormin, and Zestril for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases.

Featured Story: Why do earnings reports matter?

Analyst Recommendations for AstraZeneca (LON:AZN)

Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.